Bionano Genomics, Inc. (BNGO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bionano Genomics, Inc. on September 19, 2019. The Company is an emerging growth company incorporated in Delaware with principal executive offices in San Diego, California. The filing addresses Item 8.01 (Other Events) regarding preliminary financial guidance for the third quarter of 2019.
Key Financial Metrics
The filing provides preliminary revenue guidance for the three months ended September 30, 2019. No data regarding profit, cash flow, margins, debt, or liquidity is included in this specific report.
- Q3 2019 Revenue Guidance: $2.6 million to $3.1 million
- Q3 2018 Actual Revenue: $2.8 million
Material Changes Versus Prior Period
The Company anticipates total revenue for the three months ended September 30, 2019, to range between $2.6 million and $3.1 million. This represents a potential decrease of approximately 7% at the low end or an increase of approximately 11% at the high end compared to the $2.8 million reported for the same period in 2018.
Guidance, Outlook, and Management Commentary
Management has issued preliminary revenue estimates for the third quarter of 2019. The Company explicitly states that this estimate is preliminary and does not present all information necessary for a full understanding of its financial performance for the period. No other risks, contingencies, or unusual items are detailed in this filing.
Investor Verification Checklist
- Verify the final audited revenue figures for the quarter ended September 30, 2019, once the official 10-Q is filed.
- Review the upcoming 10-Q for details on operating expenses, net loss, and cash burn rate, as these are not provided in this 8-K.
- Monitor subsequent filings for any updates to the revenue range or changes in business strategy.